Follicular Lymphoma | Clinical

FDA Considers Parsaclisib for Approval in FL, MZL, and MCL

November 01, 2021

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.

Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell Lymphoma

October 25, 2021

A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients